To order thisdetailed 350+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Key Inclusions
§ A detailed assessment of thecurrent market landscape, including information on drug developer(s), phase ofdevelopment (marketed, clinical and preclinical / discovery stage) of leadcandidates, target immune checkpoints, their respective mechanisms of action(inhibitory or stimulatory), type of therapeutic modality used(monoclonal antibody, antibody fragment, small molecule and others), route ofadministration (intravenous, subcutaneous, oral and others), target diseaseindication, target therapeutic area and type of therapy (monotherapy,combination therapy and both).
§ A detailed analysis of more than590 completed, ongoing and planned clinical studies of next generation immunecheckpoint inhibitors and stimulators, highlighting prevalent trends acrossvarious relevant parameters, such as current trial status, trial registrationyear, phase of development, study design, leading industry sponsors / collaborators (interms of number of trials conducted), trial focus, type of target, targetindication(s), target therapeutic area(s), enrolled patients population andregional distribution.
§ Detailed profiles of developersof next generation immune checkpoint modulators (shortlisted on the basisof the number of pipeline products), featuring an overview of the company, itsfinancial information (if available), a detailed description of itsproduct portfolio and recent collaborations. In addition, each profile includesan informed future outlook.
§ An in-depth analysis of morethan 490 grants that have been awarded to research institutes engaged in nextgeneration immune checkpoint therapy-related projects, in the period between2016 and 2019 (till November), including analysis based on importantparameters, such as year of grant award, amount awarded, administrationinstitute center, funding institute center, support period, type of grantapplication, purpose of grant award, grant mechanism, popular target immunecheckpoints, responsible study section, focus area, prominent program officers,and type of recipient organizations. It also features a detailed analysis basedon the types of target immune checkpoints and therapeutic areas, along with amultivariate grant attractiveness analysis based on parameters, such as grantamount, support period, type of grant application and number of diseaseindications under investigation.
§ An analysis of the partnershipsthat have been established in the recent past, covering R&D collaborations,licensing agreements (specific to affiliated technology platforms andproduct candidates), product development and commercialization agreements,clinical trial agreements, manufacturing agreements, mergers and acquisitions,manufacturing and service agreements, and other relevant types of deals.
§ An insightful competitivenessanalysis of biological targets, featuring a [A] three-dimensional bubblerepresentation that highlights the targets that are being evaluated for nextgeneration immune checkpoint therapy development, taking into consideration thenumber of lead molecules based on a particular target, phase of development ofcandidate therapies, number of grants and number of publications [B] afive-dimensional spider-web analysis, highlighting the most popular immunecheckpoint targets.
§ An analysis of the big biopharmaplayers engaged in this domain, featuring a heat map based on parameters, suchas number of therapies under development, target disease indications,partnership activity and target portfolio.
§ Informed estimates of theexisting market size and the future opportunity for next generation immunecheckpoint inhibitors and stimulators, over the next decade. Based on multipleparameters, such as disease prevalence, anticipated adoption of next generationcheckpoint modulator therapies and their likely selling price, we have providedinformed estimates on the evolution of the market for the period 2020-2030.
The report alsofeatures the likely distribution of the current and forecasted opportunityacross important market segments, mentioned below:
- Target Disease Indication
§ Breast Cancer
§ Chronic LymphocyticLeukemia
§ Colorectal Cancer
§ Head and Neck Cancer
§ Lung Cancer
§ Lupus Nephritis
§ Melanoma
§ Multiple Myeloma
§ Primary Sjögren'sSyndrome
§ Others
- Target Immune Checkpoint
§ B7-H3
§ CD38
§ CD40
§ CD47
§ Others
- Mechanism of Action
§ Inhibitory
§ Stimulatory
- Therapeutic Modality
§ Monoclonal Antibody
§ Small Molecule
- Type of Therapy
§ Monotherapy
§ Combination Therapy
- Route of Administration
§ Intravenous
§ Subcutaneous
§ Others
- Key Geographical Regions
§ North America
§ Europe
§ Asia-Pacific and theRest of the World
To request samplepages, please visit this - https://www.rootsanalysis.com/reports/303/request-sample.html
Key QuestionsAnswered
§ Who are the leading industry players engaged in the nextgeneration immune checkpoint inhibitors and stimulators market?
§ What are the most important next generation immunecheckpoint targets?
§ For which disease indications are next generation immunecheckpoint therapies being developed?
§ What are the key factors that are likely to influence theevolution of this market?
§ What kind of initiatives have been undertaken by big pharmaplayers engaged in this domain?
§ Which partnership models are commonly adopted bystakeholders in this industry?
§ How is the current and future market opportunity likely tobe distributed across key market segments?
You may also beinterested in the following titles:
1. NeoantigenTargeted Therapies Market, 2019-2030
2. BispecificAntibody Therapeutics Market (4th Edition),2019-2030
3. GlobalStem Cells Market: Focus on Clinical Therapies,2020-2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
